How Does CBD Oil Work? The Endocannabinoid System Explained

Last updated: January 2026

This guide is for Australian patients, carers, and healthcare professionals who want a clear, evidence-based explanation of how cannabidiol (CBD) oil works in the human body. CBD does not produce intoxication. Instead, it modulates a network of receptors and signalling molecules called the endocannabinoid system (ECS), as well as several other receptor systems, to influence processes including pain signalling, inflammation, mood, and sleep. The sections below explain each mechanism in plain language, with notes on what the current evidence does and does not support.

What Is the Endocannabinoid System?

The endocannabinoid system is a biological signalling network found throughout the central and peripheral nervous systems, immune tissues, skin, gut, and most major organs. It was identified in the early 1990s during research into how THC (tetrahydrocannabinol) affects the brain. Scientists discovered that humans produce their own cannabinoid-like molecules — called endocannabinoids — that act on the same receptors.

The ECS has three core components:

• Endocannabinoids: Naturally produced lipid-based signalling molecules, primarily anandamide (AEA) and 2-arachidonoylglycerol (2-AG).
• Receptors: Protein structures embedded in cell membranes — chiefly CB1 and CB2 receptors — that endocannabinoids and plant-derived cannabinoids bind to or modulate.
• Enzymes: Proteins that synthesise endocannabinoids on demand and break them down after use — primarily FAAH (fatty acid amide hydrolase) and MAGL (monoacylglycerol lipase).

The ECS operates as a retrograde signalling system. When a receiving neuron is overactivated, it releases endocannabinoids that travel backwards across the synapse to reduce the activity of the sending neuron. This feedback mechanism is central to how the body maintains homeostasis — the stable internal balance required for normal physiological function.

How Does CBD Interact With CB1 and CB2 Receptors?

Unlike THC, CBD does not bind strongly or directly to CB1 or CB2 receptors. Instead, it acts as a negative allosteric modulator at CB1 receptors, meaning it changes the shape of the receptor in a way that reduces the ability of THC and other agonists to activate it fully. This is one reason why CBD can partially offset the intoxicating effects of THC in full-spectrum preparations.

At CB2 receptors — found predominantly in immune cells, the spleen, and peripheral tissues — CBD shows weak partial agonist activity. CB2 receptor modulation is associated with regulation of immune responses and inflammatory signalling, though the clinical significance in humans requires further study.

CBD also inhibits the enzyme FAAH, which breaks down anandamide. By slowing anandamide degradation, CBD indirectly raises circulating anandamide levels, allowing the ECS's own signalling to continue for longer. Anandamide plays a role in mood regulation, pain perception, appetite, and memory.

Which Other Receptor Systems Does CBD Influence?

CBD's pharmacological profile extends beyond the ECS. Researchers have identified activity at several other receptor systems, which helps explain its broad range of reported effects.

Serotonin (5-HT1A) Receptors

CBD acts as a partial agonist at 5-HT1A receptors at higher concentrations. These receptors are involved in anxiety, mood, sleep, and nausea regulation. This interaction is considered relevant to the anxiolytic and antiemetic effects observed in some preclinical and clinical studies, although dose-dependency is significant.

Opioid Receptors

CBD has been shown to modulate mu and delta opioid receptors indirectly, potentially contributing to pain modulation pathways. It does not bind these receptors as a classical opioid agonist, and there is no evidence it produces opioid-like dependence. Some researchers are investigating whether CBD could support opioid-sparing strategies in pain management, but this remains an area of active clinical research.

Dopamine (D2) Receptors

CBD shows partial agonist activity at D2 and D3 dopamine receptors. Dopamine pathways are involved in reward processing, motor control, and certain psychiatric conditions. This interaction is the subject of ongoing research into CBD's potential role in conditions involving dopamine dysregulation.

TRPV1 (Vanilloid) Receptors

CBD activates transient receptor potential vanilloid type 1 (TRPV1) channels, which are involved in pain and heat sensation, as well as inflammatory signalling. Prolonged activation of TRPV1 by CBD can desensitise the receptor, reducing its response to pain stimuli over time.

GPR55 Receptors

CBD acts as an antagonist at GPR55 — sometimes called the "orphan receptor" — which is involved in bone density regulation, cancer cell proliferation signalling, and blood pressure modulation. Research here is early-stage.

What Affects How Quickly CBD Works?

Onset time varies considerably depending on the administration method. The table below summarises typical onset ranges observed in pharmacokinetic studies. Individual variation is substantial and influenced by body weight, metabolic rate, fed versus fasted state, and product formulation.

CBD is highly lipophilic (fat-soluble). Taking an oral CBD product with a fatty meal can increase absorption by two to five times compared with a fasted state, which has meaningful implications for consistent dosing.

CBD Isolate vs Full-Spectrum: Does It Matter Pharmacologically?

Australian medicinal cannabis products are generally categorised as CBD isolate, broad-spectrum, or full-spectrum. The distinction has pharmacological relevance beyond marketing.

• CBD isolate: Contains only purified cannabidiol. Predictable dosing, no THC, preferred where drug testing is a concern or where other cannabinoids are clinically contraindicated.
• Broad-spectrum: Contains CBD plus other cannabinoids and terpenes with THC removed or reduced to below 1 mg/dose thresholds.
• Full-spectrum: Contains the full range of cannabinoids including THC (within legal limits), terpenes, and flavonoids. Associated with the proposed "entourage effect" — the hypothesis that cannabinoids and terpenes act synergistically, with the combination producing different pharmacodynamic effects than isolated compounds.

The entourage effect remains an active area of research. Some clinical evidence, including work published on Epidiolex (a pharmaceutical CBD isolate), demonstrates significant efficacy from isolated CBD alone. However, observational data from Australian medicinal cannabis registries suggests many patients report preferring full-spectrum preparations. Clinicians should consider the patient's occupation, drug testing requirements, and THC sensitivity when selecting a product type.

Dosing Considerations: What Does the Evidence Say?

There is no universally established therapeutic dose for CBD. Effective doses in clinical trials have ranged from 5 mg/day to over 1,500 mg/day depending on the condition studied. In Australia, medicinal CBD is a Schedule 4 prescription medicine when above 150 mg/day, or available as a Schedule 3 pharmacist-only medicine (Epidyolex) for specific paediatric epilepsy indications.

General principles drawn from clinical pharmacology research include:

• Start low and titrate gradually — CBD shows a bell-shaped dose-response curve in some studies, meaning higher doses do not always produce proportionally greater effects.
• Allow adequate time at each dose level before increasing — typically two to four weeks to assess response.
• Consistency of administration timing and food co-ingestion improves pharmacokinetic predictability.
• CBD inhibits cytochrome P450 enzymes (CYP3A4, CYP2C19), which can alter metabolism of other medications including warfarin, clobazam, and certain antiepileptics. This is clinically significant and requires prescriber review.

Australians seeking medicinal CBD should discuss options with their GP or a medicinal cannabis specialist. Access is available via the Therapeutic Goods Administration (TGA) Special Access Scheme or through authorised prescribers.

Frequently Asked Questions

Does CBD get you high?

No. CBD does not bind meaningfully to CB1 receptors in the way THC does and does not produce intoxication or euphoria. It is non-psychotomimetic at therapeutic doses. Products containing THC alongside CBD may produce psychoactive effects depending on the ratio and dose.

Is CBD legal in Australia?

CBD is legal in Australia when obtained through legitimate medical or pharmacy channels. It is a Schedule 4 prescription medicine above 150 mg/day. A low-dose Schedule 3 CBD product (Epidyolex 100 mg/mL oral solution) is available via pharmacists for certain paediatric epilepsy conditions. Recreational use is not legally permitted. State and territory regulations vary on possession and driving impairment rules — check your local jurisdiction before use.

How long does it take for CBD oil to work?

Onset depends on the administration method. Sublingual oils typically take 15–45 minutes; oral capsules may take 1–2 hours. Some therapeutic effects, particularly those related to inflammation or sleep, may require consistent use over several weeks before full benefit is observed. Single-dose effects and cumulative effects differ.

Can CBD interact with my other medications?

Yes. CBD inhibits key liver enzymes responsible for metabolising many common medications, including blood thinners, antiepileptics, and some antidepressants. This can raise or lower drug levels to clinically significant degrees. Always inform your prescriber of all medications and supplements before starting CBD.

What is the endocannabinoid system's role in overall health?

The ECS is involved in regulating a wide range of physiological processes including pain perception, immune function, mood, appetite, memory, sleep, and reproductive function. It acts as a modulatory system that helps the body maintain internal balance (homeostasis). Disruption of ECS function has been proposed as a contributing factor in several chronic conditions, though research is ongoing.

Sources

• Therapeutic Goods Administration – Cannabidiol (CBD) products: tga.gov.au/resources/resource/guidance/medicinal-cannabis-guidance-documents
• Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids. British Journal of Pharmacology. 2008;153(2):199–215. doi.org/10.1038/sj.bjp.0707442
• Blessing EM et al. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015;12(4):825–836. doi.org/10.1007/s13311-015-0387-1
• Millar SA et al. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Frontiers in Pharmacology. 2019;10:1365. doi.org/10.3389/fphar.2019.01365
• Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE): acre.org.au
• National Institute on Drug Abuse – Cannabidiol (CBD): nida.nih.gov/research-topics/cannabidiol-cbd
• Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biological Psychiatry. 2016;79(7):516–525. doi.org/10.1016/j.biopsych.2015.07.028